Subject: The Investment Journal: Biotech Holdings Ltd. PTY
From: The Investment Journal (TheInvestmentJournal@excite.com)
Date: Tue Apr 23 2002 - 16:52:08 EDT
Issue 23˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0 Journal˙FFFFA0˙FFFFA0˙FFFFA0 April 2002
˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0˙FFFFA0 BIOTECH HOLDINGS LTD.
The Company: Biotech is a pharmaceutical company based in
to make use of insulin, the hormone that controls blood sugar levels.˙FFFFA0 Currently available insulin-sensitizers such as Avandia and Actos have huge sales volumes˙FFFFA0 -- over $700 million annually in the case of Avandia, and over $1 Billion for Actos˙FFFFA0 -- despite a number of drawbacks including potential liver toxicity.˙FFFFA0 The success of these drugs demonstrates the tremendous potential for an effective and safe insulin sensitizer such as DIAB II.
The Potential Market: The market for Type II Diabetes drug worldwide is estimated to be more than $10 billion annually.
Biotech˙FFFF92s first goal is to bring DIAB II onto the market in
In addition to its prescription drug business, Biotech has a non-prescription, personal care products division which is showing steady growth.˙FFFFA0 In addition to its growing private label business, this division is planning to launch a new line of high-margin cosmetic products, which will be sold primarily in the
Biotech˙FFFF92s revenues are set to grow sharply as markets for DIAB II open up, as non-prescription revenues grow and as the implications of the above-mentioned patents are pursued, with potential for royalty payments from major pharmaceutical companies. In his Report to Shareholders, the President of Biotech concluded: We look forward with enthusiasm to developments in the coming months.
There has been growing investor interest and substantial volumes in trading of BIOHF shares.˙FFFFA0 Since January 2002 trading has averaged nearly 1 million shares per week.˙FFFFA0 This suggests to some market watchers that a strong base is being formed, with the next step being a significant upward movement.˙FFFFA0˙FFFFA0 Research the growth potential of this special situation while the Company that developed, controls and markets DIAB II is still trading as a penny stock.
The Investment Journal: The information herein has been obtained from sources which are believed to be reliable, but there are no guarantees as to its accuracy or completeness. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Biotech Holdings has not paid any cash or shares for its appearance on this report.˙FFFFA0 Some or all employees at The Investment Journal may hold shares in companies featured. We do not recommend or constitute "buy" or "sell" signals or advisories for our readers. The Investment Journal is not a securities broker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange Commission nor any state securities regulation authority. Consult with your financial advisor before making any financial decisions.
This Newsletter is intended for our opt-in readers only. If you have received this email in error,
˙FFFFA0you may remove your address by e-mailing firstname.lastname@example.org.
This archive was generated by hypermail 2b28 : Wed Apr 24 2002 - 05:13:56 EDT